Needham Maintains Buy on KalVista Pharma, Maintains $35 Price Target
Portfolio Pulse from Benzinga Newsdesk
Needham analyst Serge Belanger maintains a Buy rating on KalVista Pharma (NASDAQ:KALV) with a maintained price target of $35.
March 11, 2024 | 7:52 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Needham analyst Serge Belanger maintains a Buy rating on KalVista Pharma with a $35 price target.
The reaffirmation of a Buy rating and a $35 price target by Needham indicates a strong positive outlook on KalVista Pharma by market analysts. This could lead to increased investor confidence and potentially drive up the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 90
RELEVANCE 100